BioXcel Therapeutics (BTAI) Receivables - Other (2018 - 2019)
BioXcel Therapeutics' (BTAI) quarterly Receivables - Other came in at $46000.0 in Q2 2019, down 34.29% year-on-year from $70000.0 in Q2 2018, and down 60.0% quarter-over-quarter from $115000.0 in Q4 2018.
BioXcel Therapeutics (BTAI) Receivables - Other (2018 - 2019) Analysis & Trends
BioXcel Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $46000.0 for Q2 2019.
- On a quarterly basis, Receivables - Other fell 34.29% year-over-year to $46000.0 in Q2 2019; TTM through Jun 2019 was $46000.0, a 34.29% decrease from a year earlier, with the FY2018 full-year figure at $115000.0, changed N/A from the prior year.
- Receivables - Other retreated to $46000.0 in Q2 2019 per BTAI's latest filing, from $115000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $115000.0 in Q4 2018 and bottomed at $44000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 46,000.00 |
| Jun 30, 2019 | 46,000.00 |
| Dec 31, 2018 | 115,000.00 |
| Dec 31, 2018 | 115,000.00 |
| Sep 30, 2018 | 49,000.00 |
| Sep 30, 2018 | 49,000.00 |
| Jun 30, 2018 | 70,000.00 |
| Jun 30, 2018 | 70,000.00 |
| Mar 31, 2018 | 44,000.00 |
| Mar 31, 2018 | 44,000.00 |